
Cases of active tuberculosis have been reported worldwide with the use of therapeutic agents that inhibit zzso necrosis factor zzso zzso zzso has a central role in zzso infection and zzso zzso progression of recently acquired tuberculosis infection or zzso of remotely acquired infection should be expected with the use of zzso zzso The available zzso and zzso evidence for the two currently approved agents, zzso and zzso shows that the risk of development of active tuberculosis is greater with zzso zzso skin testing zzso should be undertaken before any significant zzso therapy including these agents, though the possibility of zzso reactions in zzso populations must be borne in zzso A positive zzso should be followed by medical assessment and chest zzso as well as by other tests judged appropriate by the physician to identify active zzso Active tuberculosis must be treated appropriately before initiation of treatment with an zzso zzso Treatment of zzso tuberculosis can be considered on an individual basis for zzso patients receiving zzso agents when significant risk factors for infection are zzso 

